Friday, July 10, 2026

pharma

TORAY INTERNATIONAL U.K

Toray International U.K is a pharma organization headquartered in GB. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USP

GB HQ
2 Employees
EMA registrant Type
Company details
Status
Public
HQ
GB
Employees
2
Programs
1
Drugs
8
Patents
0
Clinical program

950P1V02

Phase 1 · other · Bladder cancer, Cholangiocarcinoma, Colorectal Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Gastric Cancer, Melanoma, Ovarian Cancer, Palpable Subcutaneous Malignant Lesions, Primary Peritoneal Cancer, Renal Cell Carcinoma, Solid Tumor

950P1V02 for Bladder cancer, Cholangiocarcinoma, Colorectal Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Gastric Cancer, Melanoma, Ovarian Cancer, Palpable Subcutaneous Malignant Lesions, Primary Peritoneal Cancer, Renal Cell Carcinoma, Solid Tumor is a Phase 1 program (other) at Toray International U.K. Limited with 1 ClinicalTrials.gov record(s).

Internal code 950P1V02

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Toray International U.K. Limited
Phase
Phase 1
Modality
other
Indication
Bladder cancer, Cholangiocarcinoma, Colorectal Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Gastric Cancer, Melanoma, Ovarian Cancer, Palpable Subcutaneous Malignant Lesions, Primary Peritoneal Cancer, Renal Cell Carcinoma, Solid Tumor
Status
active
Trials
1